RE:Worst before better.Alex1726 wrote: Francois21 wrote: And, if we have an approval before year end, this means that from start to end, we will have bring to the market a new drug in 4 years only.
Prometic was established in 1993 or 1995 , i don't exactly remember when, but it doesn't really matter.
If you look at the last financial statement for the period ended march 31 on page 17 you read that the share capital was $507 992 M and that does not include the contributed surplus, that means that so far, by now , PLI has spent more that half a billion to generate $20 M a year , plasminogen for congenital deficiency that will be approved will probably ad $40M yearly.
That is a fact , and financiel markets evaluate facts , not promises. I am a shareholder and really hope PLI will known big success , i also hope that that the commercial potential of the small molecules will be evaluate diligently. I don't trust P.L. for that. Let's hope the members of the board will do what they're supposed to do it it was necessary.
Ok! Now you take one sentence in a context, and try to make a point with it in an another context????
Well, from scratch to end, plasminogen still could be approved within 4 years.
Now let's talk your real point.
You took an horrible short cut from 1993 until today.... And there's large part of the history that is missing.
Since they acquired from Cambridge the affinity technology in 1999, they have spent a lot of money in R&D. This true.
It's true that so far the purification revenues are around $20M a year.
PID could be a $40M yearly.
So, for now, with your logic, PLI spent $500M to build $60M a year of revenues. So it's about 9 times the revenues.
I've seen a lot of people buying buldings for 15 times the revenues.
PPPS is not a building, I know. But it still an asset.
And this asset is potected by patent, and have a real value, like any building. This is also a fact.
And this asset now will also allow to bring other products, such as IVIG, that could go in the $100M a year. Also, other proteins and I'm not including other application for plasminogen.
And, this $ 500M also include PBI-4050 and others molecules, which could easily fill the gap one day if it goes to the market.
So, there also a big fact that a large part of that $500M isn't simply burned money, but a creation of assets of value.
This is a fact that the market will have to consider one day....
But, until these things are on the market at full throttle, we still burning cash, and that's also a fact.
The right decision for the commercial potential (JV for PBI-4050) will have to be take for the sake of the balance sheet!!!